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Abstract
Background: Adjuvant tumor cell vaccine with chemotherapy against non-small cell lung cancer (NSCLC) shows limited
clinical response. Whether it provokes effective cellular immunity in tumor microenvironment is questionable. Concomitant
active tuberculosis in NSCLC (TBLC) resembles locoregional immunotherapy of tumor cell vaccine; thus, maximally enriches
effective anti-tumor immunity. This study compares the survival and immunological cell profile in TBLC over NSCLC alone.
Methods: Retrospective review of NSCLC patients within 1-year-period of 2007 and follow-up till 2010.
Results: A total 276 NSCLC patients were included. The median survival of TBLC is longer than those of NSCLC alone (11.6
vs. 8.8 month, p,0.01). Active tuberculosis is an independent predictor of better survival with HR of 0.68 (95% CI,
0.48,0.97). Squamous cell carcinoma (SCC) (55.8 vs. 31.7%, p,0.01) is a significant risk factor for NSCLC with active TB. The
median survival of SCC with active tuberculosis is significantly longer than adenocarcinoma or undetermined NSCLC with TB
(14.2 vs. 6.6 and 2.8 months, p,0.05). Active tuberculosis in SCC increases the expression of CD3 (46.4624.8 vs. 24.0616.0,
p,0.05), CXCR3 (35.1616.4 vs. 19.2613.3, p,0.01) and IP-10 (63.5621.9 vs. 35.5621.0, p,0.01), while expression of FOXP3
is decreased (3.560.5 vs. 13.363.7 p,0.05, p,0.05). Survival of SCC with high expression of CD3 (12.1 vs. 3.6 month,
p,0.05) and CXCR3 (12.1 vs. 4.4 month, p,0.05) is longer than that with low expression.
Conclusions: Active tuberculosis in NSCLC shows better survival outcome. The effective T lymphocyte infiltration in tumor
possibly underlies the mechanism. Locoregional immunotherapy of tumor cell vaccine may deserve further researches.
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Introduction
Non-small cell lung cancer (NSCLC) remains the leading cause
of cancer death worldwide[1]. Chemotherapy alone has been the
standard care in advanced disease, albeit the effect is subopti-
mal[2,3]. Adjuvant immunotherapy in combination with chemo-
therapy has been reported to be an alternative, which improves
quality of life without the increase of side effect. Hence,
understanding the host immune responses to NSCLC is essential
to tailor the use of immunotherapeutic strategies.
The ‘‘immune surveillance theory‘‘ holds that all tumor cells
express antigenic markers capable of eliciting immune responses
which prevent the outgrowth of malignant cells[4]. However,
cellular immunity is usually ineffective because neoplasms have
mechanism to evade the host immune response [5,6]. Firstly, tumor
antigens are usually poorly immunogenic because they are
perceived by the immune system as ‘‘self’’ and ‘‘alter self’’ antigens.
Secondly, tumor cells may induce functional suppression of T cell,
and conferring resistance to T cells-induced apoptosis. In contrast,
increased T cell infiltration in tumor site has been reported to be
positively associated with survival outcome in NSCLC [5,6].
Therefore, correction of cancer-related host immune dysregu-
lation accounts for an appealing strategy of anti-cancer treatment.
Purified protein derivative of M. tuberculosis (PPD) enhances the
production of inducible protein-10 (IP-10), the ligand of CXCR3,
in human lungs [7,8] to recruit activated T cells. Increased
CXCR3 expression in tumor nests is associated with prolonged
survival and more inflammatory cell infiltration in patients with
non-small cell lung cancer (NSCLC) [9]. Tumor cell vaccine, such
as tuberculosis (TB) Bacillus Calmette-Gue ´rin (BCG) and heat-
killed Mycobacterium vaccae suspension (SRL172), have been used as
non-specific immunostimulator against several types of human
cancers with variable clinical response[10,11]. For advanced
NSCLC, combination of SRL172 with chemotherapy showed
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[12].
The wide variation of efficacy of tumor cell vaccine raised a
question of whether and to what extent is the T cell immunity
provoked by systemic injection of tumor cell vaccine enriches in
the tumor microenvironment to potentiate effective immunity
against tumor[13,14] In a tuberculosis endemic country, it is
possible to approach it[15] by looking at the immunological cell
profile in tumor microenvironment when NSCLC has superim-
posed active TB happening in close vicinity[15]. Furthermore, this
clinical scenario resembles the locoregional immunotherapy of
tumor cell vaccine for NSCLC, and suggests the development of a
constant and maximally enriched T cell immunity nearby tumors.
This study primarily aims to compare the outcome in NSCLC
patients with concomitant active TB over NSCLC alone patients, in
terms of overall survival. Furthermore, the expression of immuno-
logical cell profile adjacent to tumors in either group is also studied.
Materials and Methods
Study population
We performed a retrospective review of active tuberculosis in
advanced NSCLC patients in Chang Gung Memorial Hospital (a
tertiaryreferral medical center) during the 1-yearperiod of2007 and
followed uptheir clinicaloutcomes till 2010. Informed consents were
obtained for all stored samples used for this study. Determination of
activeTBinfectionstartedfromthereviewofpositiveacid-fastsmear
from sputum, bronchial wash or broncho-alveolar lavage fluid in
advanced NSCLC patients, followed by the specific focus on those
with positive TB growth to assure the existence of viable
mycobacteria. Hence, active TB infection qualified both positive
acid-fast smear and positive culture for TB. Subsequently, the chest
X-ray or CT scan were reviewed to include patients presenting same
lobar distribution of TB and cancerous lesions.
Staging and treatment of advanced NSCLC
The scheme of 2009 AJCC 7
th edition for TNM staging was
used for study patients. Platinum-based chemotherapy was the
standard care for stage IV and stage IIIB patients. Stage IIIA
patients received concurrent chemoradiotherapy (CCRT) or
platinum-based neoadjuvant chemotherapy, and surgical resection
was considered for whom have been downstaged successfully.
Performance status is measured by ECOG scoring system runs
from 0 to 5 [16]. Patients with an ECOG performance status more
than two were treated with single-agent chemotherapy or best
supportive care alone decided by in charge physician.
Treatment for tuberculosis
Patients with concomitant active tuberculosis received standard
treatment with two months isoniazide, rifampicin, pyrazinamide and
ethambutol combination, following by four months combination with
isoniazide, rifampicin and ethambutol. For patients whose treatment
of NSCLC overlapped with that of TB; the former was postponed at
least one month after the start of anti-tuberculosis therapy. The
appropriate timing to resume the NSCLC treatment was decided by
in charge physician based on patient’s performance status.
Immunohistochemical (IHC) staining
Paraffin-embedded specimens were retrieved. Rabbit anti-human
antibodies to CD3 (Dako A/S, Glostrup, Denmark), CD4 (NeoMar-
kers, Thermo Fisher Scientific, Fremont, CA, U.S.A.), CD8 (BioCare
Medical, Concord, CA, U.S.A.), CD56 (Dako A/S, Glostrup,
Denmark), CD 68 (Dako A/S, Glostrup, Denmark), iNOS (Santa
Cruz Biotechnology, CA, U.S.A.), CXCR3 (BD Biosciences Pharmin-
gen, NJ, USA), IP-10 (Santa Cruz Biotechnology, CA, U.S.A.), CD25
(Novocastra, Newcastle upon Tyne, UK) and FOXP3 (ab20034;
Abcam, Cambridge, UK) were obtained. The staining intensity in
tumor cells was assessed in comparison to normal bronchial epithelium
as an internal positive control. Staining specificity was evaluated by
negative controls in which the primary antibody had taken the place of
n o r m a lm o u s e( f o rC D 3 ,C D 4 ,C D 5 6 ,C D 6 8 ,C D 2 5a n dF O X P 3 )a n d
normal rabbit (for CD8, iNOS, CXCR3 and IP-10) non-immune IgG.
The IHC slides were assessed under a light-microscope at X400
magnification. All nucleated cells in tumor islet cells and stroma cells
(including tumoral, structural and infiltrative inflammatory cells) were
counted by reader blinded for survival outcome information. The
percentage of cell marker-positive nucleated cells of total nucleated cells
in selective tumor islets and stromal areas was calculated and expressed
as cells/100 nucleated cells.
Statistical analysis
All quantitative data were expressed as mean values and standard
deviations. Non-parametric approaches were used since most data
were not normally distributed. The Mann–Whitney test was used to
compare numeric variables between two groups, and the x
2 test was
used for categorical variables. Univariate analyses of survival used
the log-rank test to examine effects of baseline clinical factors.
Variables with a value of p,0.1 was made to enter a multivariate
analysis with Cox’s regression model for identifying independent
predictor of survival. All analyses were conducted using the
Table 1. Baseline patients characteristics (N=276).
Variables No, (%)
Age, yr, mean6SD 67.069.2
Male sex 192 (69.6)
Performance status
ECOG # 1 148 (53.6)
ECOG $ 2 128 (46.4)
Stage
Stage IIIA 11 (4.0)
Stage IIIB 98 (35.5)
Stage IV 167 (60.5)
Pathological subtype
Adenocarcinoma 129 (46.7)
Squamous cell carcinoma 100 (36.2)
NSCLC, undetermined 47 (17.1)
Smoking status
Smoker or ex-smoker 172 (62.3)
Non- smoker 104 (37.7)
Treatment
Chemotherapy 171 (62.0)
Radiotherapy 36 (13.0)
Target therapy 216 (78.3)
BSC alone 72 (26.1)
Tuberculosis
With TB 52 (18.8)
Without TB 224 (81.2)
NSCLC: non-small cell lung cancer.
BSC: best supportive care, TB: tuberculosis.
doi:10.1371/journal.pone.0033226.t001
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Chicago, IL) and GraphPad Prism software package (v. 5;
GraphPad Prism Software Inc, San Diego, CA). All comparisons
with a p-value less than 0.05 were considered statistically significant.
Results
Patients characteristics
A total 276 advanced NSCLC patients were included, with 11
(4.0%) stage IIIA, 98 (35.5%) stage IIIB and 167 (60.5%) stage IV.
One hundred fifteen patients received first-line platinum-based
doublet, with gemcitabine in 63 (54.8%), docetaxel in 18 (15.7%),
paclitaxol in 13 (11.3%), vinorelbine in 16 (13.9%) and
pemetrexed in 5 (4.3%). Thirty patients received first-line single
agent chemotherapy, with gemcitabine in 16 (53.3%), docetaxel in
8 (26.7%), paclitaxol in 2 (6.7%), vinorelbine in 4 (13.3%). Fifty-
nine and seventy-two patients were respectively placed on first-line
target therapy and best supportive care alone. In active TB group,
nine (17.3%) had suspicious old pulmonary TB lesions based on
image studies and four (7.7%) had documented history of previous
anti-TB therapy. Eight (15.4%) out of fifty-two showed biopsy-
proven caseous granulomatous inflammation on histology. Table 1
shows the baseline characteristics of all patients.
Active Tuberculosis as an independent predictor of
survival outcome
Predictors of survival outcome are shown in Table 2. In
univariate analysis, better performance status, TB infection, stage
III of NSCLC and receiving treatment are significant predictors
for survival outcome with HR of 0.43 (95% CI, 0.33,0.52), 0.61
(95% CI, 0.43,0.86), 0.62 (95% CI, 0.48,0.79) and 0.54 (95%
CI, 0.41,0.72), respectively. In multivariate analysis, active TB
remains one of the independent predictors of survival outcome
with HR of 0.68 (95% CI, 0.48,0.97). Figure 1 shows the survival
curve of NSCLC patients with or without active TB. The median
survival of concomitant active TB is longer than those without TB
(11.6 vs. 8.8 month, p,0.01).
Squamous cell carcinoma is a risk factor for concomitant
active tuberculosis
Table 3 shows the clinical factors of NSCLC patients with or
without active tuberculosis. The risk of squamous cell carcinoma (55.8
vs. 31.7%), male gender (82.7 vs. 66.5%) and smoker (78.8 vs. 58.5%)
are significantly higher for NSCLC with active TB. Multivariate
analysis shows that squamous cell carcinoma (ORs 2.09; 95% CI,
1.06,4.14, p,0.05) is the single independent risk factor.
Table 2. Predicting factors of survival outcome by univariate and multivariate analysis.
Median Univariate Multivariate
Variables (No.) survival HR (95% CI) p-value HR (95% CI) p-value
(month)
Performance status
ECOG # 1 (148) 13.7
ECOG $ 2 (128) 5.9 0.43 (0.33,0.55) ,0.01 0.41 (0.29,0.57) ,0.01
Tuberculosis
With TB (52) 11.6
Without TB (224) 8.8 0.61 (0.43,0.86) ,0.01 0.68 (0.48,0.97) ,0.05
Pathological subtype
Squamous cell carcinoma(100) 11.1
Adenocarcinoma (129) 8.4 0.73 (0.51,1.05) 0.10
NSCLC, undetermined (47) 8.7 0.83 (0.59,1.17) 0.29
Gender
Female (84) 10.7
Male (192) 8.7 0.83 (0.63,1.08) 0.16 0.63 (0.48,0.83) ,0.05
Stage
Stage III (109) 12.5
Stage IV (167) 8.2 0.64 (0.50,0.83) ,0.01 0.62 (0.47,0.80) ,0.01
Smoking status
Non-smoker (104) 9.4
Smoker or ex-smoke (172) 9.0 0.91 (0.71,1.17) 0.47
Treatment
With treatment (204) 11.6
BSC alone (72) 6.6 0.54 (0.41,0.72) ,0.01 0.90 (0.63,1.30) 0.58
NSCLC: non-small cell lung cancer, HR: hazard ratio, BSC: best supportive care, TB: tuberculosis.
doi:10.1371/journal.pone.0033226.t002
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outcome in squamous cell carcinoma patients
Comparison of survival outcome stratified by tuberculosis
infection and histology are shown in Figure 2A (with TB) and
Figure 2B (without TB). In NSCLC with concomitant active TB,
the median survival is significantly longer in squamous cell
carcinoma than adenocarcinoma and undetermined NSCLC (14.2
vs. 6.6 and 2.8 months, p,0.05). For patient without TB, survival
is not significantly different between three histology groups (8.2,
9.1 and 8.9 month, p=0.27).
Increases in CD3, CXCR3 and IP-10 expression in
squamous cell carcinoma with concomitant active
tuberculosis
Immunological cell and chemokine profile adjacent to squa-
mous cell carcinoma was studied by immunohistochemical stain to
assess the markers representative of T lymphocyte (CD3, CD4,
CD8 and CD56), regulatory T cell (CD25, FOXP3) macrophage
(CD68, iNOS) and related chemokine or chemokine receptor (IP-
10 and CXCR3). The indices presented by percentage of each
marker adjacent to squamous cell carcinoma is shown in Table 4.
Compared to squamous cell carcinoma alone, concomitant active
TB significantly increases the expression of CD3 (46.4624.8 vs.
24.0616.0, p,0.05), CXCR3 (35.1616.4 vs. 19.2613.3, p,0.01)
and IP-10 (63.5621.9 vs. 35.5621.0, p,0.01), while expression of
FOXP3 is significantly decreased (3.560.5 vs. 13.363.7 p,0.05).
For adenocarcinoma with concomitant active TB, significantly
higher expression of CD3 and CXCR3 are also noted. (Table S1)
Increases in CD3, CXCR3 expression is associated with
better survival outcome in squamous cell carcinoma
patients
The survival outcome analysis of high or low immunohistochem-
icalmarkerindicesdivided bymedianinsquamouscellcarcinomais
shown in Table 5. Tumor with high expression of CD3 (12.1 vs.
Figure 1. Kaplan-Meier survival curve of lung cancer patients with and without active tuberculosis (log rank test, p,0.01). Green line:
patients with TB. Blue line: patients without TB.
doi:10.1371/journal.pone.0033226.g001
Table 3. Analysis of clinical factors associated with active
tuberculosis in NSCLC patients.
With TB (%) Without TB (%)
Variables N=52 N=224 p-value
Age, yr, mean6SD 67.469.6 66.7610.2 0.95
Male sex 82.7 66.5 ,0.05
Performance status
ECOG # 1 53.8 53.6 1.00
ECOG $ 2 46.2 46.4
Stage
Stage III 44.2 38.4 0.44
Stage IV 55.8 61.6
Pathological subtype
Adenocarcinoma 32.7 50.0 ,0.01
*
Squamous cell
carcinoma
** 55.8 31.7
NSCLC, undetermined 11.5 18.3
Smoking status
Smoker or ex-smoker 78.8 58.5 ,0.01
Non- smoker 21.2 41.5
Treatment
Chemotherapy 61.5 62.1
Radiotherapy 11.5 13.4
Target therapy 71.1 79.9
BSC alone 25.0 26.3 0.97
*comparison of squamous vs. non-squamous cell carcinoma
**(ORs 2.09; 95% CI, 1.06,4.14, p, 0.05) by multivariate logistic regression test
NSCLC: non-small cell lung cancer, BSC: best supportive care, TB: tuberculosis.
doi:10.1371/journal.pone.0033226.t003
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shows better median survival than those with low expression, while
other markers are not associated with survival outcome. Figure 3
representatively demonstrates the images showing high and low
expression of CD3, CXCR3 and FOXP3. For adenocarcinoma,
level of expression for each inflammatory marker is not associated
with survival outcome. (Table S2)
Discussion
The present study has demonstrated that NSCLC with active
TB is more frequently found in squamous cell carcinoma. With
concomitant active TB, NSCLC patients show a better survival
outcome; especially in squamous cell carcinoma, which is
associated with increased CD3- and CXCR3-expressing cells
within tumor.[17,18,19]
A clinicopathological analysis reported by Tamura et al. have
shown that mycobacteriosis is often adjacent to preexisting lung
cancer. [20] The walls of encapsulated caseous nodules may be
invaded by NSCLC, especially squamous cell carcinoma featuring
local invasiveness; thereby, leading to tuberculosis reactivation. Our
result reveals that active TB infection in NSCLC is an independent
predictor of better survival. There is abundant evidence in the earlier
literature that remission, regression and even total disappearance of
tumors may occur when mycobacterium infection co-exists. [21]
However, treatment with tumor cell vaccine preparation from heat-
killed Mycobacterium vaccaesuspension (SRL172) for advanced NSCLC
has only shown limited survival benefit.[12] One of the aims of tumor
cell vaccine therapy is correcting the imbalance of Th1 and Th2 cell
immunity established by cancer cells. [22,23] These include:
induction of T lymphocytes accumulation [24], upregulation of
Th1 cytokines, such as interferon-c [25], and suppression of Th2
immunity [26]. However, whether these immune reactions provoked
by intradermal injection of SRL172 are effectively enriched nearby
cancer cells has never been confirmed.
By studying NSCLC in close vicinity to active tuberculosis, it
resembles locoregional immunotherapy of tumor cell vaccine for
lung cancer. The inflammatory profile nearby tumor in this
condition is higher than those without TB, in terms of CD3,
CXCR3 and IP-10 for squamous cell carcinoma, and CD3 and
CXCR3 for adenocarcinoma. Moreover, when analyzing inflam-
matory burden to survival, it reveals that higher infiltration of
CD3- and CXCR3-expressing cells are associated with better
survival in squamous cell carcinoma. This result suggests that
locoregional immunotherapy possibly enables enrichment of
effective anti-tumor immunity nearby tumor, but appears to be
important for the clinical outcomes in patients with squamous cell
carcinoma.
On the other hand, our results show that CD3 and CXCR3
rather than IP-10 are the markers associated with survival benefit.
There are two possible explanations to it. Firstly, IP-10 is not the
ligand exclusively required by CXCR3 in order to activate T
lymphocyte [8], whereas CXCL9 and CXCL11 could play the
similar function. Secondly, the activation of T lymphocyte not only
Figure 2. Kaplan-Meier survival curve of (A) NSCLC with active TB grouped by histology (log rank test, p,0.05). (B) NSCLC without TB
grouped by histology (log rank test, p=0.27). Green line: SCC, Blue line: adenocarcinoma, Yellow line: undetermined NSCLC. SCC: squamous cell
carcinoma NSCLC: non-small cell lung cancer
doi:10.1371/journal.pone.0033226.g002
Table 4. Immunohistochemical marker indices of squamous
cell carcinoma with or without active tuberculosis.
Marker indices With TB Without TB
%, ( mean6SD) N=13 N=18 p-value
CD3 46.4624.8 24.0616.0 ,0.05
CD4 6.4612.2 2.062.0 0.29
CD8 10.1610.1 10.866.9 0.48
CD68 19.2612.4 16.069.3 0.80
iNOS 53.4631.9 39.5635.5 0.31
CD56 6.363.5 8.467.7 0.86
CXCR3 35.1616.4 19.2613.3 ,0.01
IP-10 63.5621.9 35.5621.0 ,0.01
CD25 31.662.9 28.962.3 0.47
FOXP3 3.560.5 13.363.7 ,0.05
TB: tuberculosis.
doi:10.1371/journal.pone.0033226.t004
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suppressive cells recruited and tamed by tumor. The emerging
understandingof regulatoryT cells(Treg) significantly improvesour
knowledge of immune system evasion and how it enables tumor
progression.[22,27,28] Our study also provides evidence that
expression of FOXP3; as a marker for Treg, is decreased in
squamous cell carcinoma with active TB. Dumitriu et al. has shown
that NSCLC promotes the differentiation of Treg through dendritic
cell via a TGF-beta 1 dependent mechanism[29]. In light of this,
report from MacKinnon et al. revealed that blockade of galectin-3
could possibly inhibit the IL-4/IL-13 driven alternative macro-
phage activation which is critical in building a tumor friendly
extracellular matrix[30]. Therefore, gaining better insight of the
immunosuppressive property of tumor microenvironment underlies
the responsiveness of tumor cell vaccine treatment. The major
limitation of current study is the retrospective property per se;
thereby, the samples qualified for immunohistochemical stain are
limited due to lack of prospective standardization. However, the
trend of survival outcome is similar with the main clinical results.
Additionally, the possibility of synergistic effect or interaction
between the anti-tuberculosis medication and the chemotherapeutic
agents could not be excluded.
In conclusion, this study shows that NSCLC with active TB has
better survival outcome. The effective T cell immunity nearby
tumor possibly underlies the mechanism. Locoregional treatment
of tumor cell vaccine for NSCLC may deserve further researches.
Table 5. Survival outcome analysis of high or low
immunohistochemical marker indices divided by median in
squamous cell carcinoma.
Markers Median survival (month) p-value
CD3
low 3.6
high 12.1 ,0.05
CD4
low 7.6
high 8.5 0.80
FOXP3
low 13.0
high 8.1 0.49
CXCR3
low 4.4
high 12.1 ,0.05
IP-10
low 4.5
high 9.9 0.37
doi:10.1371/journal.pone.0033226.t005
Figure 3. Representative image of immunohistochmical stain demonstrating immunological markers with high and low expression
respectively for CD3 (A) (B), CXCR3 (C) (D), and FOXP3 (E) (F). Magnification6400.
doi:10.1371/journal.pone.0033226.g003
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